CHOLESTENIX LIMITED
Company number 08771706 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
1. Executive Summary
Cholestenix Limited is a micro-entity biotechnology R&D company that has operated with persistent negative equity since incorporation, culminating in a proposal to strike off. The latest accounts show net liabilities of £93,000 and no fixed assets, confirming a business model that has not achieved commercial viability. Without an immediate capital injection or strategic transaction, the company’s future is limited to an orderly dissolution.
2. Strategic Assets
- Research Capability: The SIC code (72110) confirms a focus on biotechnology R&D, which may have generated intellectual property not capitalised on the balance sheet.
- Lean Cost Structure: With only two employees and minimal overhead, the company has kept operational costs low, but this has not been sufficient to reach profitability.
- Director Commitment: The going concern statement in the accounts indicates continued belief in the venture, and filing compliance has been maintained despite financial strain.
- PSC Network: The presence of a corporate shareholder (Oxandia Limited) and an individual academic (name shown to subscribers) among persons with significant control may provide access to expertise and potential funding sources.
3. Growth Opportunities
- Technology Licensing or Sale: If the research has commercial potential, it could be licensed to or acquired by a larger biotech or pharmaceutical firm, offering a return for creditors and shareholders.
- Grant or Collaborative Funding: Non-dilutive funding from research councils or innovation agencies could sustain development without immediate revenue pressure.
- Strategic Partnership: A joint venture with a university or industry partner could bring resources and validation to the technology.
- Turnaround Capital: New investors could restructure liabilities and refocus R&D on a more commercially viable path, though time is critical given the strike‑off proposal.
4. Strategic Risks
- Imminent Dissolution: The proposal to strike off is the most pressing risk; if implemented, the company will cease to exist and any remaining value will be lost.
- Insolvency and Director Exposure: Negative net assets over multiple years raise the risk of director disqualification or claims of wrongful trading, despite the going concern assertion in the accounts.
- Lack of Revenue: The company has not demonstrated an ability to generate revenue from its R&D, making it dependent on external funding that has not materialised.
- Short‑Term Debt Concentration: All liabilities are due within one year, creating severe liquidity pressure and leaving no margin for error.